JSON

prostate adenocarcinoma

^ http://www.ebi.ac.uk/efo/EFO_0000673


An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.

Tumors or cancer of the PROSTATE.

Synonyms: Neoplasm, Prostate, Cancer, Prostate, Adenocarcinoma of the Prostate, PROSTATIC NEOPL, Prostate Neoplasms, Adenocarcinoma of prostate (disorder), Prostatic Neoplasms, Cancers, Prostatic, NEOPL PROSTATIC, NEOPL PROSTATE, Prostate Neoplasm, Prostatic Neoplasm, Cancer of the Prostate, Neoplasms, Prostate, Prostatic Cancer, Neoplasm, Prostatic, Prostatic Cancers, PROSTATE NEOPL, adenocarcinoma of prostate, Cancer of Prostate, Prostate Cancer, Cancer, Prostatic, Cancers, Prostate, Neoplasms, Prostatic, Prostate Cancers

Term info

SNOMEDCT definition citation

SNOMEDCT:399490008

bioportal provenance

Cancer, Prostate[accessedResource: MSH:D011471][accessDate: 05-04-2011], Cancers, Prostatic[accessedResource: MSH:D011471][accessDate: 05-04-2011], An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.[accessedResource: NCIt:C2919][accessDate: 05-04-2011], Prostatic Neoplasms[accessedResource: MSH:D011471][accessDate: 05-04-2011], Cancer of the Prostate[accessedResource: MSH:D011471][accessDate: 05-04-2011], Neoplasms, Prostate[accessedResource: MSH:D011471][accessDate: 05-04-2011], NEOPL PROSTATE[accessedResource: MSH:D011471][accessDate: 05-04-2011], Cancers, Prostate[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostate Neoplasms[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostatic Neoplasm[accessedResource: MSH:D011471][accessDate: 05-04-2011], Neoplasm, Prostate[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostate Neoplasm[accessedResource: MSH:D011471][accessDate: 05-04-2011], Cancer, Prostatic[accessedResource: MSH:D011471][accessDate: 05-04-2011], Tumors or cancer of the PROSTATE.[accessedResource: MSH:D011471][accessDate: 05-04-2011], Neoplasm, Prostatic[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostate Cancer[accessedResource: MSH:D011471][accessDate: 05-04-2011], PROSTATE NEOPL[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostatic Cancers[accessedResource: MSH:D011471][accessDate: 05-04-2011], Adenocarcinoma of prostate (disorder)[accessedResource: SNOMEDCT:399490008][accessDate: 05-04-2011], NEOPL PROSTATIC[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostate Cancers[accessedResource: MSH:D011471][accessDate: 05-04-2011], Neoplasms, Prostatic[accessedResource: MSH:D011471][accessDate: 05-04-2011], adenocarcinoma of prostate[accessedResource: DOID:2526][accessDate: 05-04-2011], PROSTATIC NEOPL[accessedResource: MSH:D011471][accessDate: 05-04-2011], Adenocarcinoma of the Prostate[accessedResource: NCIt:C2919][accessDate: 05-04-2011], Cancer of Prostate[accessedResource: MSH:D011471][accessDate: 05-04-2011], Prostatic Cancer[accessedResource: MSH:D011471][accessDate: 05-04-2011]

gwas trait

true

term editor

James Malone, Tomasz Adamusiak